Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

Over the past couple of years, Bellicum Pharmaceuticals has made several changes that have streamlined their pipeline and their OpEx. Consequently, I have had to adjust my thesis and expectations. Bellicum was only a few quarters away from being a commercial company and collecting revenue. Now, the company is back to proof-of-concept and Phase I trials.

Bellicum Pharmaceuticals: Narrowing The Thesis And Simplifying The Investment

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT

Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

The stock price of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) has increased by over 15% pre-market. This is why it happened.

BLCM Stock Price Increases Over 15% Pre-Market: Why It Happened

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of a case report using the company's CaspaCIDe (inducible caspase-9, or iC9) safety switch. The letter to the editor titled “Utility of Safety Switch to Abrogate CD 19 CAR T Cell-Associated Neurotoxicity” appeared as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. Link to article.

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

The stock price of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) is trading at over 40% pre-market. This is why it happened.

BLCM Stock Price Increases Over 40% Pre-Market: Why It Happened

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

BJ`s Wholesale Club Holdings Inc

Liminal BioSciences

360 Finance Inc - ADR

Vaccinex Inc

Meridian Bioscience

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Bet on Rising P/E With These 5 Top-Ranked Stocks

Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum's first dual switch GoCAR-T® product candidate that incorporates the company's iMC activation and CaspaCIDe® safety switch technologies.

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer. The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.

Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)? The smart money sentiment can provide an answer to this question.

Is Bellicum Pharmaceuticals Inc (BLCM) A Good Stock To Buy?

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know

Cardinal Health

Fidelity National Financial

Glu Mobile

Qualys

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Ignored Trick to Pick 5 Winning Stocks

Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of $6.025 and each pre-funded warrant to purchase one share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of $6.024. The exercise price of each pre-funded warrant is $0.001 per share and the exercise price of each accompanying warrant to purchase common stock is $6.50 per share.

Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

Shares of Bellicum Pharmaceuticals Inc. plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company said it was slashing its workforce by 79% as part of a restructuring, following disappointing data from a trial of its pancreatic cancer treatment. The interim trial results of BPX-601 were "encouraging" in terms of safety and GoCAR-T cell activation, but clinically meaningful efficacy was not observed.

Bellicum Pharmaceuticals to cut 79% of staff after disappointing trial data, stock suffering record plunge

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum's existing healthcare-dedicated institutional investors.

Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory metastatic pancreatic cancer. Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful efficacy as measured by RECIST criteria was not observed.

Bellicum Announces Interim BPX-601 Data and Corporate Restructuring

HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences.

Bellicum to Participate in Two Upcoming Virtual Conferences

Bellicum Pharmaceuticals' stock continues to be pounded into submission by the market. Now that the market has obliterated any premium left in the stock, I am looking to accumulate.

Bellicum Pharmaceuticals: Accumulating At This Valuation

HOUSTON, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences.

Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q2 2020 Results - Earnings Call Transcript

Management to host webcast and conference call on Thursday,  August 6, 2020 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Thursday,  August 6, 2020 at 5 p.m. ET / 2 p.m. PT

News for Bellicum Pharmaceuticals Stock (BLCM)